IL187509A0 - Raf inhibitor compunds and methods of use thereof - Google Patents

Raf inhibitor compunds and methods of use thereof

Info

Publication number
IL187509A0
IL187509A0 IL187509A IL18750907A IL187509A0 IL 187509 A0 IL187509 A0 IL 187509A0 IL 187509 A IL187509 A IL 187509A IL 18750907 A IL18750907 A IL 18750907A IL 187509 A0 IL187509 A0 IL 187509A0
Authority
IL
Israel
Prior art keywords
compunds
methods
raf inhibitor
raf
inhibitor
Prior art date
Application number
IL187509A
Other languages
English (en)
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of IL187509A0 publication Critical patent/IL187509A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL187509A 2005-05-20 2007-11-20 Raf inhibitor compunds and methods of use thereof IL187509A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68317505P 2005-05-20 2005-05-20
PCT/US2006/019280 WO2006125101A2 (en) 2005-05-20 2006-05-18 Raf inhibitor compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
IL187509A0 true IL187509A0 (en) 2008-03-20

Family

ID=37432152

Family Applications (1)

Application Number Title Priority Date Filing Date
IL187509A IL187509A0 (en) 2005-05-20 2007-11-20 Raf inhibitor compunds and methods of use thereof

Country Status (14)

Country Link
US (1) US7566716B2 (https=)
EP (1) EP1902056A2 (https=)
JP (1) JP2008540674A (https=)
KR (1) KR20080038278A (https=)
CN (1) CN101263142A (https=)
AU (1) AU2006247118A1 (https=)
BR (1) BRPI0610863A2 (https=)
CA (1) CA2609299A1 (https=)
IL (1) IL187509A0 (https=)
MX (1) MX2007014510A (https=)
NO (1) NO20076553L (https=)
RU (1) RU2007147382A (https=)
WO (1) WO2006125101A2 (https=)
ZA (1) ZA200710969B (https=)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006028862A1 (de) * 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
WO2008042639A1 (en) 2006-10-02 2008-04-10 Irm Llc Compounds and compositions as protein kinase inhibitors
US20100298314A1 (en) * 2006-12-20 2010-11-25 Schering Corporation Novel jnk inhibitors
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
CN101855222A (zh) * 2007-05-10 2010-10-06 通用电气健康护理有限公司 对大麻素cb2受体具有活性的咪唑并(1,2-a)吡啶和相关化合物
UY31292A1 (es) * 2007-08-14 2009-03-31 Imidazoles biciclicos fusionados
MX2010001636A (es) * 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
EP2062893A1 (en) * 2007-10-18 2009-05-27 Bayer Schering Pharma AG Fused imidazoles for cancer treatment
PE20091561A1 (es) * 2008-02-29 2009-10-30 Array Biopharma Inc Compuestos inhibidores de raf y metodos para su uso
ES2392482T3 (es) * 2008-02-29 2012-12-11 Array Biopharma, Inc. Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF
JP2011513332A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
JP2011513331A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
CN102712646A (zh) 2009-08-28 2012-10-03 阵列生物制药公司 Raf抑制剂化合物及其使用方法
US20130018033A1 (en) 2009-08-28 2013-01-17 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
US20120157453A1 (en) 2009-08-28 2012-06-21 Genentech, Inc. Raf inhibitor compounds and methods of use thereof
WO2011025951A1 (en) 2009-08-28 2011-03-03 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
EP2470532A1 (en) 2009-08-28 2012-07-04 Array Biopharma, Inc. 1h-pyrazolo [ 3, 4-b]pyridine compounds for inhibiting raf kinase
CN102666498A (zh) * 2009-08-28 2012-09-12 健泰科生物技术公司 Raf抑制剂化合物及其使用方法
KR101233082B1 (ko) 2010-02-25 2013-02-14 주식회사 이큐스앤자루 신규한 이미다졸피라진 유도체 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 항바이러스 치료용 약학적 조성물
BR112012030909A2 (pt) 2010-06-04 2020-08-18 Abraxis Bioscience, Llc métodos de tratamento de câncer pancreático
CN102406646B (zh) * 2010-09-20 2015-09-09 北大方正集团有限公司 芳基脲衍生物用于制备治疗移植排斥药物的用途
EP2661434A4 (en) 2011-01-06 2014-07-09 Beta Pharma Canada Inc NEW UREAS FOR THE TREATMENT AND PREVENTION OF CANCER
SI2694510T1 (sl) 2011-04-07 2016-02-29 Bayer Intellectual Property Gmbh Imidazopiridazini kot inhibitorji AKT kinaze
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
US9273046B2 (en) 2011-12-31 2016-03-01 Beigene, Ltd. Fused tricyclic compounds as Raf kinase inhibitors
US9670231B2 (en) 2013-06-28 2017-06-06 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170145025A1 (en) 2015-11-19 2017-05-25 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2905980T3 (es) 2016-05-26 2022-04-12 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
BR112018076534A2 (pt) 2016-06-20 2019-04-02 Incyte Corporation compostos heterocíclicos como imunomoduladores
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
AU2017382870B2 (en) 2016-12-22 2022-03-24 Incyte Corporation Benzooxazole derivatives as immunomodulators
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
EP3558990B1 (en) 2016-12-22 2022-08-10 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
JP7341060B2 (ja) 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
EP3732285A1 (en) 2017-12-28 2020-11-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
CR20200520A (es) 2018-03-30 2021-03-09 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2019217821A1 (en) 2018-05-11 2019-11-14 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
EA202191482A1 (ru) * 2018-11-26 2021-12-14 Янссен Сайенсиз Айрлэнд Анлимитед Компани Другие гетероароматические соединения, обладающие активностью против rsv
EP4010342A1 (en) 2019-08-09 2022-06-15 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
WO2021067217A1 (en) 2019-09-30 2021-04-08 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
CN116217416A (zh) * 2022-12-31 2023-06-06 黄淮学院 一种苯并咪唑类药物中间体3-硝基-4-乙基氨基苯甲醇的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203052A3 (en) * 1999-10-08 2004-06-28 Gruenenthal Gmbh Bicyclic imidazo-3-yl-amine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
DE10019714A1 (de) * 2000-04-20 2002-01-10 Gruenenthal Gmbh Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
DE10050663A1 (de) * 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
AU2002224927A1 (en) * 2000-12-13 2002-06-24 Basf Aktiengesellschaft Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
TWI312347B (en) * 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
DE10150172A1 (de) 2001-10-11 2003-04-30 Morphochem Ag Neue Verbindungen, die Protein Tyrosin Phosphatase 1B (PTP-1B) inhibieren
WO2004072081A1 (en) 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2005120513A1 (en) 2004-06-09 2005-12-22 Oncalis Ag Protein kinase inhibitors
DE102004044884A1 (de) 2004-09-14 2006-05-24 Grünenthal GmbH Substituierte bizyklische Imidazo-3-yl-amin-Verbindungen

Also Published As

Publication number Publication date
MX2007014510A (es) 2008-02-05
CN101263142A (zh) 2008-09-10
AU2006247118A1 (en) 2006-11-23
WO2006125101A2 (en) 2006-11-23
JP2008540674A (ja) 2008-11-20
US7566716B2 (en) 2009-07-28
US20060281751A1 (en) 2006-12-14
NO20076553L (no) 2008-02-19
KR20080038278A (ko) 2008-05-06
CA2609299A1 (en) 2006-11-23
ZA200710969B (en) 2009-03-25
EP1902056A2 (en) 2008-03-26
RU2007147382A (ru) 2009-06-27
WO2006125101A3 (en) 2007-03-29
BRPI0610863A2 (pt) 2010-08-03

Similar Documents

Publication Publication Date Title
IL187509A0 (en) Raf inhibitor compunds and methods of use thereof
IL189771A0 (en) Raf inhibitor compounds and methods of use thereof
IL185024A0 (en) Raf inhibitor compounds and methods
EP1951736A4 (en) INTERFERING MULTICIBLATION RNA AND METHODS OF USE AND DESIGN
IL186490A0 (en) Multicyclic compounds and methods of their use
IL176958A0 (en) Compounds and methods of use
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
GB2446843B (en) Amplifier circuit and methods of operation thereof
IL213843A0 (en) 4-aminotetracyclines and methods of use thereof
IL207843A0 (en) Raf inhibitor compounds and methods of use thereof
GB2441489B (en) Stylet apparatuses and methods of manufacture
IL189602A0 (en) Indenoisoquinolinone analogs and methods of use thereof
PL2099796T3 (pl) Związki azaindolilowe i sposoby ich zastosowania
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
ZA200709751B (en) Thiazole compounds and methods of use
GB0817892D0 (en) Engineered listeria and methods of use thereof
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
ZA200808017B (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
IL190226A0 (en) Organometallic compounds and methods of use thereof
EP1812451A4 (en) COMPOUNDS AND METHODS OF USE THEREOF
ZA200804681B (en) Inhibitors of C-Met and uses thereof
ZA200900896B (en) Aza-benzofuranyl compounds and methods of use
EP1883404A4 (en) P38 INHIBITORS AND METHODS OF USE
GB0520930D0 (en) Composition and method of use
ZA200901009B (en) Aza-benzothiophenyl compounds and methods of use